Lyra Therapeutics Statistics

Total Valuation

LYRA has a market cap or net worth of $13.46 million. The enterprise value is -$2.84 million.

Market Cap	13.46M
Enterprise Value	-2.84M

Important Dates

The next estimated earnings date is Thursday, March 20, 2025, after market close.

Earnings Date	Mar 20, 2025
Ex-Dividend Date	n/a

Share Statistics

LYRA has 65.46 million shares outstanding. The number of shares has increased by 29.41% in one year.

Current Share Class	65.46M
Shares Outstanding	65.46M
Shares Change (YoY)	+29.41%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	0.51%
Owned by Institutions (%)	22.66%
Float	46.48M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.97
Forward PS	25.04
PB Ratio	0.65
P/TBV Ratio	0.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.64, with a Debt / Equity ratio of 1.71.

Current Ratio	3.64
Quick Ratio	3.45
Debt / Equity	1.71
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -186.18% and return on invested capital (ROIC) is -57.56%.

Return on Equity (ROE)	-186.18%
Return on Assets (ROA)	-42.29%
Return on Invested Capital (ROIC)	-57.56%
Return on Capital Employed (ROCE)	-105.71%
Revenue Per Employee	$16,716
Profits Per Employee	-$1.11M
Employee Count	88
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

In the past 12 months, LYRA has paid $50,000 in taxes.

Income Tax	50,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -95.89% in the last 52 weeks. The beta is -0.13, so LYRA's price volatility has been lower than the market average.

Beta (5Y)	-0.13
52-Week Price Change	-95.89%
50-Day Moving Average	0.19
200-Day Moving Average	0.26
Relative Strength Index (RSI)	57.83
Average Volume (20 Days)	907,818

Short Selling Information

The latest short interest is 2.14 million, so 3.27% of the outstanding shares have been sold short.

Short Interest	2.14M
Short Previous Month	2.13M
Short % of Shares Out	3.27%
Short % of Float	4.60%
Short Ratio (days to cover)	1.67

Income Statement

In the last 12 months, LYRA had revenue of $1.47 million and -$97.61 million in losses. Loss per share was -$1.52.

Revenue	1.47M
Gross Profit	-48.20M
Operating Income	-67.44M
Pretax Income	-68.82M
Net Income	-97.61M
EBITDA	-67.04M
EBIT	-67.44M
Loss Per Share	-$1.52

Full Income Statement

Balance Sheet

The company has $51.63 million in cash and $35.32 million in debt, giving a net cash position of $16.30 million or $0.25 per share.

Cash & Cash Equivalents	51.63M
Total Debt	35.32M
Net Cash	16.30M
Net Cash Per Share	$0.25
Equity (Book Value)	20.62M
Book Value Per Share	0.32
Working Capital	39.49M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$77.72 million and capital expenditures -$3.18 million, giving a free cash flow of -$80.90 million.

Operating Cash Flow	-77.72M
Capital Expenditures	-3.18M
Free Cash Flow	-80.90M
FCF Per Share	-$1.24

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-4,584.91%
Pretax Margin	-6,632.36%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LYRA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-29.41%
Shareholder Yield	-29.41%
Earnings Yield	-724.95%
FCF Yield	-600.83%

Analyst Forecast

The average price target for LYRA is $4.50, which is 2,087.65% higher than the current price. The consensus rating is "Buy".

Price Target	$4.50
Price Target Difference	2,087.65%
Analyst Consensus	Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	105.05%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LYRA has an Altman Z-Score of -7.61 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.61
Piotroski F-Score	3